Goal of submitting 13 INDs, including ADCs and multiple antibodies, by 2028
Celltrion unveiled the detailed development roadmap for its new drug pipeline to global investors for the first time.
On the 14th (local time), Celltrion disclosed its new drug development achievements and detailed future development plans under the theme of ‘Innovative New Drug Pipeline Development Strategy’ on the main track, the main stage of the JP Morgan Healthcare Conference event. The JP Morgan Healthcare Conference is the world’s largest pharmaceutical and bioindustry investment event held annually in San Francisco, California, USA.
Seo Jin-seok, CEO of Celltrion’s Management Business Department, who made the announcement on this day, said, “Celltrion has already fully proven its ability to develop antibody biopharmaceuticals by achieving its vision of building a portfolio of 11 products by 2025 early last year.” “Based on our development experience and know-how, we will accelerate the development of next-generation new drugs,” he said.
As for new drugs, antibody drug conjugates (ADCs) and multi-antibody new drugs were presented as two-horse wagons that will drive Celltrion’s future growth. ADC is a technology that attaches a drug (payload) to an antibody to accurately target cancer cells, and polyantibody is a new drug with a structure that allows one antibody to recognize and bind to two or more targets at the same time.
First, Celltrion plans to introduce Biobetter ADC as a new drug, which is an improvement on existing treatments such as ‘CT-P70’, a non-small cell lung cancer treatment, and ‘CT-P71’, a bladder cancer treatment, which were first unveiled at World ADC last year. These treatments use the new payload ‘PBX-7016’ jointly developed by Celltrion through open innovation. PBX-7016 showed low toxicity and high tumor growth inhibition (TGI) effect during the development process, and the company plans to consider applying it to future pipelines.
In addition, we plan to sequentially develop ‘bispecific ADC’, which can target two targets at the same time, and ‘dual-payload ADC’, which maximizes treatment effect by combining two types of drugs. am.
Celltrion is also focusing on developing new multi-antibody drugs. Multiple antibody treatments are attracting attention as a treatment option to fill unmet medical needs that cannot be addressed with existing drugs. Accordingly, Celltrion also plans to focus on developing multiple antibody treatments that act selectively on cancer cells or are activated only under specific conditions. Currently, we are developing a new multi-antibody anti-cancer drug, ‘CT-P72’, which is designed to act only on cancer cells and reduces toxicity to normal cells.
CEO Seo also disclosed the annual clinical trial plan (IND) for new drug candidates. First, we plan to submit INDs for a total of 13 candidate substances, including 9 in the ADC field and 4 in the multiple antibody field, by 2028. ADC new drugs CT-P70, CT-P71, CT-P73 and multi-antibody new drugs CT-P72 completed IND submission this year, two ADC new drugs and two multi-antibody new drugs next year, three ADC new drugs in 2027, and three new drugs in 2028. plans to submit IND for one ADC new drug and one multi-antibody new drug.
CEO Seo said, “This year, two years after the development of next-generation new drugs began in earnest, four new drug candidates are scheduled to sequentially enter clinical trials, and new new drug projects will continue every year.” He added, “The leading candidate materials will be developed with extraordinary development speed and progress from non-clinical trials.” “With the results showing, Celltrion’s goal of becoming a global new drug company will quickly become a reality,” he emphasized.
In the Q&A session that followed, Celltrion Group Chairman Seo Jeong-jin personally appeared and continued communication with the investors who attended the event. Chairman Seo said, “We plan to continuously promote the development of various new drugs as well as biosimilars so that many patients can use biopharmaceuticals at reasonable prices,” and added, “Based on our rapidly expanding product portfolio, we will continue to achieve the high growth that investors expect.” .
Source: kormedi.com
